Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer.

Abstract

5034 Background: Use of targeted therapy requires identification of patients (pts) whose tumors express a specific molecular target. Several folate receptor (FR) molecular targeted drugs are in clinical development including the folate-vinca EC145. Before treatment with EC145, as part of study NCT00507741, pts underwent planar and SPECT scanning with the FR targeted, technetium-labeled imaging agent EC20 in order to evaluate whether scan results correlate with subsequent response to therapy with EC145. Methods: 45 pts with advanced ovarian cancer received 99 mTc labeled EC20. EC20 uptake for each tumor was classified as